Grafa News and Videos — Page 263

Vertex Pharmaceuticals (NASDAQ:VRTX) reported positive Phase 2b AMPLIFIED study results for inaxaplin in people with APOL1-mediated kidney disease and different levels of proteinuria.

Ionis Pharmaceuticals (NASDAQ:IONS) and Otsuka Pharmaceutical reported positive topline Phase 3 results for ulefnersen, an investigational RNA-targeted medicine for FUS-ALS.

Ligand Pharmaceuticals (NASDAQ:LGND) agreed to acquire royalty and milestone interests in Santen’s Ryjunea eye drop for a $23 million upfront payment.

Lexeo Therapeutics (NASDAQ:LXEO) agreed to acquire Mantle Therapeutics for up to $21.3 million to expand its Friedreich ataxia drug development portfolio.

GameStop (NYSE:GME) shares rose after CEO Ryan Cohen disclosed the purchase of approximately 1.15 million additional shares worth about $26.4 million.

MediWound (NASDAQ:MDWD) received an additional $3.3 million in non-dilutive funding to support development of a room-temperature-stable NexoBrid formulation for battlefield burn care.

Cognex Corporation (NASDAQ:CGNX) announced a definitive agreement to acquire RealSense, a provider of 3D robotic perception and depth-sensing camera technology, for approximately $500 million in cash.

Viking Therapeutics (NASDAQ:VKTX) announced positive topline results from a 33-week clinical study evaluating VK2735, its investigational GLP-1/GIP receptor agonist being developed for obesity treatment.

MillerKnoll (NASDAQ:MLKN) reported financial results for the first quarter of fiscal year 2027, showing improved profitability and order growth despite a decline in revenue.

AutoZone (NYSE:AZO) reported fourth-quarter and full fiscal year 2026 financial results, showing higher sales, improved profitability and continued expansion of its automotive aftermarket retail footprint.